# FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0287				
Estimated average burden					
nours per respon-	se 0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)  1. Name and Address of Reporting Person *			2. Iss	2. Issuer Name and Ticker or Trading Symbol						5. Relationship of Reporting Person(s) to Issuer						
Ciechanover Isaac E.					Atara Biotherapeutics, Inc. [ATRA]							(Check all applicable) _X_ Director 10% Owner				
(Last) (First) (Middle) 611 GATEWAY BOULEVARD, SUITE 900					3. Date of Earliest Transaction (Month/Day/Year) 09/06/2017						X Officer (give title below) Other (specify below) Chief Executive Officer					
		(Street)		4. If A	4. If Amendment, Date Original Filed(Month/Day/Year)						_X_ Form fil	ed by One Repo	rting Person	g(Check Applic	able Line)	
		NCISCO, C										Form filed by More than One Reporting Person				
(City	7)	(State)	(Zip)		Ta	ble I -	Non	-Der	ivative S	ecuritie	s Acqui	ired, Disp	osed of, or l	Beneficially	Owned	
(Instr. 3) Date		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any				ction	(A) or Disposed of (D) (Instr. 3, 4 and 5)						Ownership	7. Nature of Indirect Beneficial	
				(Month	n/Day/Year		ode	V	Amoun	(A) or t (D)	Price	(Instr. 3 a	(Instr. 3 and 4) Direct (D) O		Ownership (Instr. 4)	
Common	Stock		09/06/2017			S	<u>(1)</u>		2,200	D	\$ 15.05 (2)	439,578	139,578		I	See footnote (3)
Common	Stock		09/07/2017			Si	1)		2,200	D	\$ 14.98 ( <u>4)</u>	437,378	}		I	See footnote (3)
Common	Stock											737,767	<u>'</u>		D	
Reminder: indirectly.	Report on a	separate line	for each class of sec	Derivati	ive Securit	ies Ac	quire	Pers cont the	sons wh tained i form dis	n this fo splays a of, or Be	orm ar a curre eneficia	e not required in the second s	ection of in uired to re d OMB cor	spond un	less	EC 1474 (9- 02)
1. Title of	2	3. Transactio			ts, calls, w 4.							itle and	8 Price of	9. Number	of 10	11. Natur
Derivative Security	Conversion	n Date Execution D (Month/Day/Year) any (Month/Day		ate, if	ate, if Transaction Code Year) (Instr. 8)		of a		6. Date Exercisable and Expiration Date (Month/Day/Year)		Am Und Sec	ount of derlying urities str. 3 and	Derivative Security		Owners: Form of Derivati Security Direct (I or Indire	hip of Indirect Beneficia Ownershi (Instr. 4)
								Dat	e ercisable	Expirati	on Titl	Amount or e Number of				

### **Reporting Owners**

D (1 0 N /A)	Relationships					
Reporting Owner Name / Address	Director 10% Owner		Officer	Other		
Ciechanover Isaac E. 611 GATEWAY BOULEVARD SUITE 900 SOUTH SAN FRANCISCO, CA 94080	X		Chief Executive Officer			

### **Signatures**

/s/ Tina Gullotta, Attorney-in-Fact for Isaac E. Ciechanover	09/07/2017
Signature of Reporting Person	Date

### **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017.
- (2) The price in Column 4 is a weighted average sale price. The prices actually received ranged from \$14.85 to \$15.20. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (3) Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee.
- The price in Column 4 is a weighted average sale price. The prices actually received ranged from \$14.75 to \$15.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.